London Daily

Focus on the big picture.
Wednesday, Oct 22, 2025

More than half of Hongkongers don’t intend to take Covid-19 vaccine

More than half of Hongkongers don’t intend to take Covid-19 vaccine

Health expert says government, scientific community and the World Health Organization need to provide ‘solid scientific evidence’ to ease residents’ concerns.

In a fresh blow to the government’s plan to vaccinate every Hong Kong resident, a survey has found that more than half do not intend to take the Covid-19
shot, a rise of 17 percentage points over the past two months.

The citywide poll by the University of Hong Kong (HKU) also revealed that fewer than three in 10 residents were prepared to take the vaccine supplied by mainland Chinese company Sinovac Biotech amid concerns over its low efficacy.

The findings came as Hong Kong reported 39 new coronavirus infections on Thursday, extending a downward trend in daily caseloads for a fifth day. All but one of the cases were imported, with 20 of them untraceable.

The city’s tally stands at 10,321, with 176 related deaths after two chronically ill men, aged 47 and 66, succumbed to the disease. Three arrivals were found to be carrying a mutated, fast-spreading strain of the virus, taking the total of such cases to 20.


Pedestrians and schoolchildren wear protective masks in downtown Hong Kong.


Professor Gabriel Leung, dean of HKU’s faculty of medicine who was involved in the research, said the government, scientific community and the World Health Organization (WHO) needed to provide “solid scientific evidence” to ease residents’ concerns.

“Build trust by being honest, open and transparent and trust science,” Leung said on Thursday. “We all need to do more in explaining to the public.”

The survey comprised two independent arms of research. Based on a series of polls, the first part – involving more than 1,000 respondents polled between January 6 and 17 – showed a drop in the number of residents intending to receive a vaccination, from 63.2 per cent in November to 45.9 in January.

The second part – a weekly phone survey

of 500 to 1,000 adults – found the percentage of residents intending to get vaccinated had fallen from 67.4 per cent to 50.2 over the same period.

“Interestingly, the results of the two surveys match highly, even though they employed different sampling methods and pools of respondents, which indicate the findings are very accurate and representative of science,” Leung said.

He noted that the proportion of residents in mainland China polled on the same question in June last year was 88.6 per cent, 79.8 in South Africa and 67.9 in Singapore. But Leung said global confidence in the inoculations was broadly declining as misinformation and confusion over the shots increased.

Among the three brands of vaccines already procured by the Hong Kong government, the jabs by Pfizer-BioNTech had the highest level of acceptability, at 55.9 per cent, while AstraZeneca’s shots had the lowest, at 35.3 per cent.

Public confidence in Sinovac’s vaccines fell from 38.2 per cent to 29.5 per cent after the release of data

by the Butantan Institute, its partner in Brazil, showing an unexpectedly low efficacy rate of 50.4 per cent.

Leung did not directly address the question of whether Hong Kong should switch from the Sinovac vaccine in light of the findings, but he said he was encouraged by the WHO review of the firm’s shots for emergency use.

Hong Kong has struck deals to purchase 22.5 million doses of Covid-19 vaccines, with 7.5 million shots each coming from three suppliers: Sinovac Biotech; Fosun Pharma which offered the vaccine co-developed by Germany’s BioNTech and US-based Pfizer; and British-Swedish firm AstraZeneca.

But the city’s vaccination campaign got off to a rocky start when Chief Executive Carrie Lam Cheng Yuet-ngor initially said residents would not be allowed to choose which shots they received, only to later clarify they would be allowed a preference.

The roll-out also suffered delays after Sinovac did not deliver its doses by January as promised and failed to publish comprehensive final-stage trial data.

BioNTech’s vaccines are now expected to be the first to arrive in the later half of February after Lunar New Year. But the company is also dealing with reports of severe adverse side effects, with at least 29 elderly people dying in Norway after taking the jabs.

HKU’s research showed the public has lost confidence in the safety and effectiveness of Covid-19 vaccines, with just 45.3 per cent of respondents still believing they will be safe, down from 59.6 per cent two months ago, while 54 per cent regarded the jabs as effective, down from 67.1 per cent in November.

Leung admitted safety concerns had undermined the public’s confidence in the jabs but stressed that hesitancy over an experimental procedure was not unusual.

“It is nothing surprising,” he said. “When doctors give a new drug or needle, patients often ask about side effects and whether they really need to take it. These things happen every day in a hospital. The most important thing is how we build confidence among the public to take the vaccines.”

Professor Benjamin Cowling, head of the division of epidemiology and biostatistics at HKU’s school of public health, said the survey pattern was consistent with overseas trends but more studies were needed to determine the reasons behind the discrepancies.

Leung also revealed that HKU would apply to the government to run one of its 18 community vaccination centres and provide experts from its accidents and emergency, trauma and anaesthesiology wards who were experienced in dealing with medical emergencies arising from vaccine side effects.

Newsletter

Related Articles

0:00
0:00
Close
US Administration Under President Donald Trump Reportedly Lifts Ban on Ukraine’s Use of Storm Shadow Missiles Against Russia
‘Frightening’ First Night in Prison for Sarkozy: Inmates Riot and Shout ‘Little Nicolas’
White House Announces No Imminent Summit Between Trump and Putin
US and Qatar Warn EU of Trade and Energy Risks from Tough Climate Regulation
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Nicolas Sarkozy begins five-year prison term at La Santé in Paris
Japan stocks surge to record as Sanae Takaichi becomes Prime Minister
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
Surging AI Startup Valuations Fuel Bubble Concerns Among Top Investors
Australian Punter Archie Wilson Tears Up During Nebraska Press Conference, Sparking Conversation on Male Vulnerability
Australia Confirms U.S. Access to Upgraded Submarine Shipyard Under AUKUS Deal
“Firepower” Promised for Ukraine as NATO Ministers Meet — But U.S. Tomahawks Remain Undecided
Brands Confront New Dilemma as Extremists Adopt Fashion Labels
The Sydney Sweeney and Jeans Storm: “The Outcome Surpassed Our Wildest Dreams”
Erika Kirk Delivers Moving Tribute at White House as Trump Awards Charlie Presidential Medal of Freedom
British Food Influencer ‘Big John’ Detained in Australia After Visa Dispute
ScamBodia: The Chinese Fraud Empire Shielded by Cambodia’s Ruling Elite
French PM Suspends Macron’s Pension Reform Until After 2027 in Bid to Stabilize Government
Orange, Bouygues and Free Make €17 Billion Bid for Drahi’s Altice France Telecom Assets
×